SML0218
Bropirimine
≥98% (HPLC)
别名:
2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone, NSC 149027, PNU 54461, U 54461, U 54461S
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C10H8BrN3O
化学文摘社编号:
分子量:
266.09
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C10H8BrN3O/c11-7-8(6-4-2-1-3-5-6)13-10(12)14-9(7)15/h1-5H,(H3,12,13,14,15)
SMILES string
NC1=NC(=O)C(Br)=C(N1)c2ccccc2
InChI key
CIUUIPMOFZIWIZ-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: ≥5 mg/mL (warm DMSO)
storage temp.
room temp
Quality Level
Application
Bropirimine, an immunostimulating agent and toll like receptor (TLR7) agonist, is used in comparison with other TLR7 agonists such as imiquimod, R-848, loxoribine in interferon cell signaling research. Bropirimine may be used in experimental autoimmune encephalomyelitis (EAE) and bladder cancer research.
Biochem/physiol Actions
Bropirimine is an immunostimulant, anti-tumor agent
Bropirimine is an immunostimulating agent. The compound induces production of α and β interferons and enhances NK cell function. Bropirimine has antiproliferative effects in cancer cell lines and tumor growth in in vivo models.
signalword
Warning
hcodes
Hazard Classifications
Repr. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Sandra Demaria et al.
Oncoimmunology, 2(10), e25997-e25997 (2014-01-10)
Radiotherapy can convert malignant cells into an in situ anticancer vaccine, but is often inadequate at generating sufficient pro-inflammatory signals to optimally activate innate and adaptive immune responses. Topical imiquimod is a powerful pro-inflammatory agent with clinical activity against superficial
M Shaw et al.
Methods and findings in experimental and clinical pharmacology, 20(2), 111-114 (1998-05-30)
Paclitaxel, bropirimine and linomide therapy was evaluated in a murine prostate cancer model. All drugs were effective in impeding tumor growth but the mechanisms of action varied. Paclitaxel inhibited bcl-2 expression suggesting an apoptotic mechanism. Bropirimine, while inhibiting bcl-2 expression
M A Wynalda et al.
Xenobiotica; the fate of foreign compounds in biological systems, 33(10), 999-1011 (2003-10-14)
1. The antitumour agent bropirimine undergoes significant Phase II conjugation in vivo. Incubation of [14C]bropirimine with human liver microsomes resulted in the formation of a single product peak (M1) using high-performance liquid chromatography with radiochemical detection and was tentatively assigned
Benoit Desnues et al.
Proceedings of the National Academy of Sciences of the United States of America, 111(4), 1497-1502 (2014-01-30)
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with diverse clinical presentations characterized by the presence of autoantibodies to nuclear components. Toll-like receptor (TLR)7, TLR8, and TLR9 sense microbial or endogenous nucleic acids and are implicated in the development
J A Witjes
European urology, 31 Suppl 1, 27-30 (1997-01-01)
To explore new treatment strategies in high-risk superficial bladder cancer patients, such as recurrent carcinoma in situ (CIS) or pT1 transitional cell carcinoma after intravesical bacillus Calmette-Guérin (BCG). Mechanism of action, pharmacology and the results of clinical phase I and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持